






Paul Seddon, Katy Fidler, Sundhya Raman,  
Hilary Wyatt, Gary Ruiz, Caroline Elston, Felicity 
Perrin, Khin Gyi, Diana Bilton,  
Francis Drobniewski, and Melanie Newport
Incidence of pulmonary infection with nontuberculous 
mycobacteria (NTM) is increasing among persons with cys-
tic fibrosis (CF). We assessed prevalence and management 
in CF centers in the United Kingdom and found 5.0% of 
3,805 adults and 3.3% of 3,317 children had recently been 
diagnosed with NTM. Of those, 44% of adults and 47% of 
children received treatment.
Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms (1), broadly classifiable into 
“slow” and “rapid” growers. Many species, especially the 
slow-growing Mycobacterium avium complex (MAC), are 
known to cause disseminated disease in immunodeficient 
persons (2,3). Rapid growers include the phylogenetically 
similar M. abscessus and M. chelonae, referred to as M. ab-
scessus complex (MABSC). Such organisms have emerged 
as pathogens in immunocompetent adults, for example, af-
ter traumatic limb injuries sustained during the 2004 tsu-
nami in the Indian Ocean (4). NTM have been identified 
as pulmonary pathogens in immunocompetent middle-aged 
women with nodular bronchiectasis (5) and older men who 
smoke with upper lobe cavitation (6). Since the 1990s, 
NTM have been increasingly isolated from the sputum of 
patients with cystic fibrosis (CF) (7,8).
CF is the most frequent lethal genetic disorder of White 
persons, affecting >8,000 persons in the United Kingdom 
and 30,000 in the United States. Early death is mainly from 
chronic lung disease caused by persistent lower airway 
infection and inflammation. Important airway pathogens 
include Staphylococcus aureus and Pseudomonas aerugi-
nosa, but others, such as NTM, are playing an increasingly 
recognized role.
A multicenter prospective study of CF patients in the 
United States (9) found the prevalence of NTM in sputum 
to be 13%; MAC was the most common species (72%), 
and M. abscessus was the next most common (16%). Older 
age was the most significant predictor for a positive sputum 
culture. A multicenter CF study in France reported a preva-
lence of 6.6%, showing MABSC to be the most common; 
MAC was the next most prevalent (10). Single-center stud-
ies in Europe have found variable NTM prevalences, from 
13.3% in a center in Germany (7) to 3.8% in a center in the 
United Kingdom (8).
It is often difficult to determine whether isolation 
of NTM represents colonization or disease that requires 
treatment. Current American Thoracic Society guide-
lines (1) are helpful, but application lacks uniformity, and 
management is complicated by inducible resistance to 
antibiotics (11).
To determine the optimal management of NTM in 
CF, we first need to define the extent of the problem and 
characterize current practice. The aim of this study was to 
establish the prevalence of NTM infection in the UK CF 
community, how it is screened for, and how it is managed.
The Study
A single-page questionnaire (online Technical Appen-
dix, wwwnc.cdc.gov/EID/article/19/7/12-0615-Techapp1.
pdf) was sent to the lead CF physician in all UK pediat-
ric and adult CF centers identified by the principal UK CF 
charity, the Cystic Fibrosis Trust, in 2009. Nonresponders 
were followed up with by email or telephone. The local 
research ethics committee deemed the study did not require 
ethical approval.
Results were tabulated and basic statistical analysis 
performed by using Microsoft Excel 2007 (Microsoft, Red-
mond, WA, USA). Because M. chelonae and M. absces-
sus have common phenotypic characteristics and not all 
samples were fully sequenced by a reference laboratory, 
we combined these for reporting as MABSC.
Twenty-three adult and 29 pediatric UK CF centers, 
with 8,513 CF patients, were sent questionnaires. Respons-
es were received from 19 (83%) and 24 (83%) of these cen-
ters respectively, comprising 7,122 patients (3,805 adults, 
3,317 children), or 84% of the UK CF population. As ex-
pected, the prevalence of any NTM isolate was higher in 
the adult (5.0%) than in the pediatric (3.3%) population 
(Table). Fifteen adult and 17 pediatric centers cultured 
samples for NTM yearly; most remaining centers tested 
for NTM only if there was a specific clinical indication. 
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The NTM pathogens most frequently cultured were the 
rapidly growing MABSC (62% of adults, 68% of chil-
dren who were NTM-positive), followed by MAC (28% 
of adults, 27% of children). Other species (M. gordonae, 
kansasii, xenopi, fortuitum, simiae, malmoense, mucogeni-
cum, perigrinum) together made up 8% of the total. Wide 
geographic variation was noted, increasing from northwest 
to southeast, manifesting lowest prevalence in Northern 
Ireland (1.9%) and highest in South East England (7.5%) 
(Figure).
Criteria for starting treatment varied widely between 
centers. Most centers required clear clinical or radiologic 
deterioration in addition to positive cultures, but a signifi-
cantly higher proportion of adult centers (42%) than pedi-
atric centers (21%) were prepared to commence treatment 
on the basis of repeated culture or smear positivity alone. 
Despite this, similar proportions of NTM-positive adults 
and children had received specific treatment for NTM in 
the 2 years preceding the survey: 44% of adults and 47% 
of children with any NTM isolate were treated, and 62% 
of adults and 70% of children in whom >2 isolates were 
found were treated. Six adults and 2 children who had CF 
had been refused a lung transplant on the basis of persistent 
NTM infection.
Our results differ from a 2003 multicenter US survey 
(9) in 2 crucial ways. First, the overall prevalence of NTM 
of 4.2% during the study period in the United Kingdom 
was much lower than the 13% reported for the study done 
in the United States. This could be caused in part by lower 
sampling frequency, occurring annually in most UK clin-
ics, compared with 3 times annually as reported in the US 
study. The proportion of patients having >2 positive cultures 
was similar: 3.9% for the US study and 3.0% for our study. 
Furthermore, the denominator used for prevalence estima-
tion may have been overestimated in this study: it may have 
included some patients missed for annual culture; and par-
ticularly for pediatric clinics, the denominator would include 
non–sputum producers (cough swabs are normally not cul-
tured for NTM). The questionnaire we used did not specify 
which source documents respondents used; therefore, recall 
bias may be an issue. However, all UK centers extract and 
report NTM data to a national database annually.
The second striking difference between this study and 
the US study was that rapid-growing mycobacteria (espe-
cially MABSC) predominated in this survey while MAC 
predominated in the US study. Our results are more in 
keeping with subsequent European and Middle East preva-
lence studies (7,10,12). Rapid-growing mycobacteria such 
as MABSC are now recognized to be of greater clinical 
importance in CF than MAC (1), and a recent US single-
center survey (13) has shown M. abscessus to be the cur-
rent dominant NTM and to be associated with evidence of 
clinical decline.
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Table, NTM isolation rate and screening frequency among adult and pediatric cystic fibrosis clinics, United Kingdom, 2009 
CF clinic 
type 
No. clinics receiving/no. 
responding to survey (%) 
Total no. 
patients 
No. (%) clinics 
Frequency of requesting 
NTM culture 
With any NTM isolates in 
previous 2 y 
With >2 NTM isolates 
in previous 2 y 
Adult 19/23 (83) 3,805 190 (5.0) 135 (3.6) Yearly: 15 
     Every 6 months: 1 
     Every 3 months 1 
     When clinically indicated: 2 
Pediatric 24/29 (83) 3,317 110 (3.3) 74 (2.2) Yearly: 17 
     Every 6 months: 0 
     Every 3 months 0 
     When clinically indicated: 7 
*NTM, nontuberculous mycobacteria. 
 
Figure. Regional variation in percentage of cystic fibrosis patients 
in whom nontuberculous mycobacteria were isolated, United 
Kingdom, 2009. Percentages represent combined clinics within 
participating regions. Nineteen of 23 adult and 24 of 29 pediatric 
CF centers, accounting for 7,122 of 8,513 (84%) CF patients, 
participated in the survey.
As in previous studies, we found marked geographic 
variation in prevalence: Olivier et al. found higher rates 
in coastal centers in the United States (9), and Roux et 
al. found the highest prevalence in west and southwest 
France (10). The higher prevalence in the south of the 
United Kingdom could be caused by different sampling 
rates, but we found no systematic difference in screening 
policy between different UK regions. Climatic differences 
are relatively small across a small temperate island such 
as the United Kingdom. Geology could be another factor; 
NTM acquisition has been linked with water from aquifers 
(12,14) which are present mainly in the younger rocks in 
southeastern United Kingdom.
The varied threshold for instigating NTM treatment 
is perhaps not surprising in view of the lack of evidence 
to guide this. Although there is no clear evidence to jus-
tify treatment on positive cultures alone, some centers may 
have lowered their threshold in the hope that (by analogy 
with Pseudomonas aeruginosa) aggressive early treatment 
might lead to eradication. Refusal of lung transplantation is 
clearly an issue and appears to affect the threshold for treat-
ment, though the rationale for refusal by transplant centers 
remains controversial (15).
Conclusions
This survey highlights the growing importance of 
NTM as a CF pathogen, the importance of routine, stan-
dardized surveillance, and the need to find out how best 
to manage NTM in CF. This will require further research 
into environmental, microbial, and host factors influenc-
ing acquisition and disease progression of NTM in the 
CF population.
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